sever
acut
respiratori
syndrom
coronaviru
viru
respons
coronaviru
diseas
first
identifi
wuhan
hubei
china
decemb
sinc
declar
pandem
world
health
organ
march
first
discov
coronavirus
coronavirida
famili
envelop
positivesens
singlestrand
ribonucl
acid
rna
virus
genom
size
viral
group
rang
kilobas
larger
rna
virus
name
coronaviru
origin
latin
word
corona
mean
crown
halo
due
characterist
appear
twodimension
transmiss
electron
microscopi
coronavirus
clubshap
spike
peplom
cover
surfac
figur
sinc
discoveri
seven
human
pathogen
strain
identifi
within
coronavirida
famili
orthocoronavirina
subfamili
alphacoronaviru
betacoronaviru
transmiss
human
alpha
betacoronaviru
strain
thought
origin
bat
speci
rousettu
leschenaultii
clinic
present
vari
wide
rang
mild
coldlik
symptom
sever
respiratori
distress
death
alphacoronaviru
strain
along
betacoronaviru
strain
tend
caus
mild
symptom
betacoronaviru
strain
merscov
middl
east
respiratori
syndrom
coronaviru
sarscov
sever
acut
respiratori
syndrom
coronaviru
known
caus
sever
respiratori
distress
recent
histori
sever
outbreak
occur
relat
betacoronaviru
strain
figur
depict
genom
structur
sarscov
merscov
humantohuman
transmiss
primarili
occur
close
contact
respiratori
droplet
similar
mani
viral
particl
transmiss
increas
lower
temperatur
viralladen
droplet
effect
produc
due
increas
evapor
lower
rel
humid
allow
viral
particl
remain
airborn
longer
viral
particl
enter
respiratori
tract
viru
attach
pulmonari
cell
follow
endocytosi
sarscov
merscov
enter
cell
endocytosi
pathway
use
surfac
spike
protein
bind
angiotensinconvert
enzym
dipeptidyl
peptidas
receptor
ciliat
bronchial
epitheli
cell
type
ii
pneumocyt
respect
viru
enter
host
cell
viral
rna
expos
open
read
frame
translat
produc
polyprotein
polyprotein
later
cleav
form
structur
protein
rna
replicasetranscriptas
complex
respons
replic
transcript
viral
rna
viral
nucleocapsid
assembl
bud
lumen
endoplasm
reticulum
golgi
intermedi
compart
ergic
viral
nucleocapsid
encas
viral
rna
produc
new
coronaviru
virion
exocytos
complet
replic
cycl
viral
replic
summar
figur
present
brief
review
viral
origin
identif
symptom
transmiss
diagnosi
potenti
treatment
strategi
newli
identifi
strain
origin
decemb
cluster
atyp
pneumonia
case
report
wuhan
china
first
known
case
record
decemb
major
patient
diagnos
atyp
pneumonia
link
huanan
seafood
market
suggest
zoonot
origin
report
indic
earli
rapid
spread
case
doubl
everi
day
januari
declar
public
health
emerg
intern
concern
case
began
spread
around
world
march
declar
outbreak
pandem
identif
shortli
investig
began
determin
betacoronaviru
respons
identifi
figur
prior
identif
viru
call
novel
coronaviru
suggest
chang
name
human
coronaviru
avoid
confus
recent
strain
sarscov
refer
new
strain
accept
center
diseas
control
prevent
cdc
newli
identifi
human
strain
thought
relat
bat
pangolin
coronaviru
well
sarscov
genet
analysi
place
viru
genu
betacoronaviru
subgenu
sarbecoviru
lineag
b
confirm
like
origin
bat
coronaviru
batcov
analysi
reveal
one
amino
acid
differ
sarscov
pangolin
coronaviru
pangolincov
suggest
possibl
intermedi
host
symptom
patient
test
posit
symptomat
diagnos
symptom
vari
drastic
includ
fever
chill
dri
cough
sputum
product
fatigu
lethargi
arthralgia
myalgia
headach
dyspnea
nausea
vomit
anorexia
diarrhea
carrier
may
asymptomat
wherea
other
experi
acut
respiratori
distress
syndrom
ard
death
sever
seem
also
vari
age
disproportion
affect
advanc
age
preexist
chronic
medic
condit
tabl
transmiss
transmiss
occur
primarili
respiratori
droplet
also
occur
contact
contamin
surfac
viabl
viral
particl
may
remain
stainless
steel
plastic
hour
applic
current
cdc
recommend
airborn
droplet
precaut
healthcar
provid
come
contact
potenti
patient
sever
public
measur
taken
local
feder
govern
level
unit
state
reduc
rate
transmiss
includ
social
distanc
selfisol
incub
period
may
vari
known
day
coronavirus
date
median
observ
incub
period
appear
day
confid
interv
ci
day
develop
symptom
within
day
ci
day
infect
although
risk
transmiss
asymptomat
individu
may
low
still
possibl
basic
reproduct
number
number
case
directli
gener
one
case
popul
individu
suscept
report
similar
sarscov
cellular
level
viral
particl
enter
respiratori
tract
like
sarscov
use
receptor
pulmonari
cell
entri
type
transmembran
metallocarboxypeptidas
normal
physiolog
circumst
function
degrad
angiotensin
ii
modul
reninangiotensin
system
ra
viral
protein
bind
receptor
prompt
cellular
membran
fusion
endocytosi
process
depend
protein
prime
serin
proteas
mani
coronaviru
model
potenti
identifi
futur
treatment
modal
diagnosi
diagnosi
ultim
confirm
realtim
revers
transcript
polymeras
chain
reaction
rrtpcr
respiratori
blood
sampl
note
rrtpcr
positivetoneg
convers
report
day
report
detail
imag
find
suggest
although
find
nonspecif
reliabl
yet
establish
comput
tomographi
ct
find
includ
bilater
multilobar
groundglass
opac
peripher
posterior
distribut
mainli
lower
lung
lobe
less
commonli
septal
thicken
bronchiectasi
pleural
thicken
subpleur
involv
report
diseas
progress
occur
repeat
ct
scan
may
show
multifoc
consolid
pave
pattern
figur
treatment
current
definit
therapi
vaccin
viru
manag
support
sever
case
aim
improv
ard
discuss
trial
current
underway
identifi
therapeut
option
remdesivir
nucleotid
analog
inhibitor
rnadepend
rna
polymeras
previous
shown
antivir
activ
merscov
sarscov
studi
current
avail
show
inhibit
viral
replic
vitro
chloroquin
typic
use
context
malari
autoimmun
diseas
also
shown
promis
result
chloroquin
affect
glycosyl
pulmonari
cell
receptor
impair
viral
cell
entri
medicationinduc
ph
chang
within
pulmonari
cell
alkalin
also
delay
viral
replic
key
step
endosom
function
impair
similarli
hydroxychloroquin
anoth
less
toxic
potenti
effect
therapi
trial
current
underway
evalu
effect
chloroquin
hydroxychloroquin
camostat
mesyl
serin
proteas
inhibitor
identifi
potenti
treatment
option
camostat
mesyl
partial
block
entri
pulmonari
cell
inhibit
protein
prime
endocytosi
followup
studi
treatment
camostat
mesyl
current
pend
tocilizumab
human
monoclon
antibodi
receptor
ab
commonli
use
immunosuppress
treatment
rheumatoid
arthriti
system
juvenil
idiopath
arthriti
current
postul
patient
sever
manifest
experi
degre
cytokin
storm
result
ard
death
small
studi
china
found
success
treatment
sever
case
tocilizumab
small
studi
found
decreas
fever
oxygen
requir
creactiv
protein
crp
along
improv
ct
find
medic
dose
provid
lopinavir
ritonavir
proteas
inhibitor
commonli
use
treatment
prevent
human
immunodefici
viru
hiv
acquir
immunodefici
syndrom
aid
random
control
openlabel
trial
confirm
posit
adult
patient
ard
perform
use
cours
lopinavir
ritonavir
twice
daili
benefit
observ
beyond
standard
care
postul
combin
lopinavir
ritonavir
may
becom
effect
addit
interferonbeta
infb
studi
requir
confirm
find
nitazoxanid
broadspectrum
antiparasit
antivir
agent
use
treatment
variou
helminth
protozo
viral
infect
nitazoxanid
found
inhibit
low
micromolar
concentr
vitro
studi
requir
prove
vivo
efficaci
medic
advisori
caution
use
use
corticosteroid
patient
previou
data
suggest
decreas
viral
clearanc
merscov
sarscov
potenti
prolong
cours
ill
mortal
benefit
appreci
nonard
patient
specul
regard
nonsteroid
antiinflammatori
nsaid
specif
ibuprofen
caus
upregul
receptor
although
studi
avail
time
suggest
increas
risk
similarli
group
voic
concern
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
therapi
concern
due
mechan
action
upregul
receptor
use
cell
entri
studi
perform
evalu
theoret
risk
current
expert
opinion
recommend
patient
acei
arb
therapi
continu
current
drug
regimen
mani
societi
made
statement
regard
matter
detail
tabl
outcom
case
fatal
vari
geograph
final
mortal
estim
vari
weekli
mani
case
current
ongo
recent
data
suggest
case
fatal
slightli
increas
rate
document
china
case
fatal
also
vari
age
patient
age
year
patient
age
year
critic
case
uncertain
whether
figur
predict
diseas
case
fatal
unit
state
progress
throughout
unit
state
current
ongo
coronaviru
respons
pandem
one
seven
human
transmiss
coronavirus
thought
origin
bat
coronaviru
first
human
case
document
wuhan
china
decemb
thought
result
transmiss
intermedi
host
like
pangolin
humantohuman
diseas
transmiss
primarili
occur
respiratori
droplet
respiratori
tract
enter
pulmonari
cell
endocytosi
via
receptor
mean
incub
time
day
ci
day
develop
symptom
within
day
ci
day
symptom
may
vari
mild
sever
typic
viral
ill
includ
influenza
basic
reproduct
number
report
affect
advanc
age
preexist
chronic
medic
condit
final
mortal
rate
current
unknown
larg
portion
case
yet
resolv
estim
case
fatal
treatment
option
limit
support
care
manag
ard
sever
case
ongo
studi
evalu
efficaci
remdesivir
chloroquin
hydroxychloroquin
camostat
mesyl
tocilizumab
potenti
therapi
lopinavir
ritonavir
appear
effect
current
vaccin
avail
although
effort
progress
develop
vaccin
come
year
caution
use
use
corticosteroid
nonard
patient
mortal
benefit
observ
viral
clearanc
prolong
use
acei
arb
discontinu
effort
prevent
reduc
transmiss
per
current
societi
statement
